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Precis 
Postoperative radiotherapy increased RFS for stage II and III thymic carcinoma. 
Postoperative radiotherapy did not increase RFS or OS for stage II and III thymoma. 
 
 









The efficacy of postoperative radiotherapy (PORT) for thymic epithelial tumors is still 
controversial. This study aims to clarify the efficacy of PORT for Masaoka stage II and 
III thymic carcinoma and thymoma using the Japanese Association for Research on the 
Thymus (JART) database. 
Methods 
The JART database registered the records of 2,835 patients collected from 32 Japanese 
institutions from 1991 to 2010. Thymic carcinoma and thymoma at stage II or III were 
extracted. Efficacy of PORT on relapse-free survival (RFS) and overall survival (OS) 
was evaluated using the Kaplan-Meier method and the Cox regression analysis. 
Results 
A total of 1265 patients were consisted of 155 (12.3%) thymic carcinoma and 1,110 
(87.7%) thymoma cases; 895 (70.8%) at stage II and 370 (29.2%) at stage III; 403 
(31.9%) cases had PORT. PORT for stage II and III thymic carcinoma was associated 
with increasing RFS (hazard ratio, 0.48; 95% confidence interval, 0.30-0.78; P=0.003), 
but not with OS (hazard ratio, 0.94; 95% confidence interval, 0.51-1.75; P=0.536). 
PORT for stage II and III thymoma was not associated with RFS or OS (P=0.350). 
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Subgroup analysis for stage III thymoma showed no factor associated with the efficacy 
of PORT. 
Conclusion 
In this study, PORT did not increase RFS or OS for stage II and III thymoma, but 
increased RFS for stage II and III thymic carcinoma. 
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Thymic epithelial tumors are relatively rare neoplasms that originate from thymic 
epithelial cells1. They are chiefly divided into thymic carcinoma and thymoma, with 
the former accounting for 15–20% of thymic epithelial tumors2. Masaoka staging3 and 
Masaoka–Koga staging4 have been widely used for the classification of thymic 
epithelial tumors. An official uniform classification system, however, has not yet been 
established5. The mainstay treatment for thymic epithelial tumors remains surgical 
resection6. Radiotherapy (RT) has also been applied as a palliative or adjuvant therap6 
because of the radiosensitive nature of the tumors7, but the efficacy of postoperative 
radiotherapy (PORT) for thymic epithelial tumors remains unclear. An optimal 
chemotherapy regimen has not yet been determined8, 9. 
The International Thymic Malignancy Interest Group (ITMIG) provided radiation 
therapy definitions and reporting guidelines for thymic malignancies, but did not 
comment on the guidelines for PORT10, and thus the indication for PORT for thymic 
epithelial tumors is still left up to the individual judgments of respective institutes. 
We undertook this database study to clarify the efficacy of PORT for Masaoka stage II 
or III thymic carcinoma and thymoma using the Japanese Association for Research on 
the Thymus (JART) database. 
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MATERIAL AND METHODS 
Data Sources 
The JART, established by Akira Masaoka and colleagues in 1982, is a nonprofit 
research organization that contributes to the development of research on thymic 
epithelial tumors. A nationwide project to create a database for surgically treated 
thymic epithelial tumors was conducted by the JART in 2012. The records of 2,835 
patients collected from 32 leading Japanese institutions from January 1991 to 
December 2010 were registered in the JART database. The Masaoka staging system 
was applied to the classification of thymic epithelial tumors in this database. 
Institutional Review Board approval was obtained from each institution. 
Patient Selection 
Eligibility criteria were as follows: (1) histologically confirmed thymic carcinoma or 
thymoma; and (2) Masaoka stage II or III. Exclusion criteria consisted of: (1) thymic 
neuroendocrine tumor, (2) macroscopic gross residual tumor (>20% of tumor volume), 
and (3) lack of PORT information.  
Patient clinical and demographic information (gender, age, associated 
myasthenia gravis (MG), resection completeness, tumor size, affected organs, WHO 
histological classification, postoperative chemotherapy, recurrence, and prognosis) was 
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extracted from the JART database.  
 
Statistical analysis 
Age and maximum tumor diameter were summarized using mean ± standard deviation 
and median (range), whereas the categorical variables were summarized using counts 
and percentages. For continuous variables, the Wilcoxon rank-sum test was used, and 
for categorical variables, the chi-square test or Fisher’s exact test was applied as 
appropriate, to compare the patient backgrounds with or without the PORT. 
Relapse-free survival (RFS) and overall survival (OS) were calculated from the date of 
surgery. Time-to-event curves for RFS and OS were estimated by the Kaplan-Meier 
method, and differences in time-to-event curves with and without PORT were 
evaluated by the log-rank test. The hazard ratio (HR) and corresponding 95% 
confidence intervals (CIs) were calculated using the Cox proportional-hazards model 
controlling for Masaoka staging, histology, and completeness of surgery. All P-values 
were two-sided and P-values < 0.05 were considered as statistically significant. All 




This study was approved by the Kyoto University Graduate School and Faculty of 
Medicine Ethics Committee (E1904). The study was also approved by each 
participated institutional review board.  
 
RESULTS 
Patient characteristics  
The scheme of the study population of the 2,835 patients in the JART database is 
shown in Figure 1. A total of 1,265 patients with 574 males (45.4%) and a median age 
of 59 (range 18–86) years were analyzed. The diagnoses consisted of 155 (12.3%) 
thymic carcinoma and 1,110 (87.7%) thymoma cases; 895 (70.8%) of the cases were 
stage II, and 370 (29.2%) were stage III. Further, 403 (31.9%) cases had undergone 
PORT. The characteristics of these patients are reported in Tables 1a and 1b. The 
median follow-up period was 1,704 (range 0–7,741) days. 
Overall results 
The 5-year RFS proportions of the PORT group (n = 403) and the no PORT group (n = 
862) for stage II/III were 78.0% and 83.5% respectively. Although PORT tended to 
show an adverse effect (P = 0.056) on RFS, the HR of PORT to no PORT by Cox 
regression analysis adjusted for covariates (histology, staging, and residual tumor) 
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showed no significant difference between the two groups (HR, 0.76; 95% CI, 
0.58-1.01; P=0.116; Supplements 1, 2). 
Relapse-free survival for stage II and stage III thymic carcinoma 
The 5-year RFS proportions of the PORT group (n = 25) and the no PORT group 
(n=27) for stage II thymic carcinoma were 91.3% and 68.1% (Fig. 2a). For stage III 
thymic carcinoma, the 5-year RFS proportions of the PORT group (n=51) and the no 
adjuvant RT group (n=44) were 50.5% and 26.1% (Fig. 2b). The RFS HR of PORT for 
stage II and III thymic carcinoma as analyzed by Cox regression analysis adjusted for 
Masaoka stage and residual tumor was 0.48 (95% CI, 0.30–0.78; P=0.003; Table 2). 
Relapse-free survival for stage II and stage III thymoma 
The 5-year RFS proportions of the PORT group (n = 196) and the no PORT group 
(n=615) for stage II thymoma were 93.4% and 92.3% (Fig. 2c). The 5-year RFS 
proportions of the PORT group (n=119) and the no PORT group (n = 143) for stage III 
thymoma was 62.0% and 69.3% (Fig. 2d). 
The RFS HR of PORT as analyzed by Cox regression analysis adjusted for Masaoka 
stage and residual tumor was 0.98 (95% CI, 0.70–1.37; P = 0.905; Table 2). 
Subgroup analyses comparing PORT to no PORT for patients with stage III thymoma 
No factors were associated with the efficacy of PORT for stage III thymoma cases in 
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the subgroup analyses: i.e., WHO histological type, affected organ, tumor size, 
presence of MG, and completeness of resection. Any subgroup containing fewer than 
50 cases was excluded from these analyses. Each HR and 95% CI by subgroup is 
shown in Figure 3 as a forest plot. 
Overall survival for stage II and III thymic carcinoma and thymoma  
The 5-yaer OS proportions of the PORT group (n = 25) and the no PORT group (n=30) 
for stage II thymic carcinoma were 91.1% and 86.8% (Fig. 4a). The 5-year OS 
proportions of the PORT group (n = 55) and the no PORT group (n = 44) for stage III 
thymic carcinoma were 65.0% and 64.0% (Fig. 4b). 
The 5-year OS proportions of the PORT group (n=199) and the no PORT group 
(n=637) for stage II thymoma were 96.5% and 96.2% (Fig. 4c). The 5-year OS 
proportions of the PORT group (n=122) and the no PORT group (n=147) for stage III 
thymoma were 92.9% and 89.7% (Fig. 4d). 
PORT for stage II and III thymic carcinoma or thymoma was not statistically 
significantly associated with OS. The HR for combined stage II and III thymic 
carcinomas as analyzed by Cox regression analysis adjusted for Masaoka stage and 
residual tumor was 0.94 (95% CI, 0.51–1.75; P = 0.850; Table 3). The HR for 
combined stage II and III thymomas as analyzed by Cox regression analysis adjusted 
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for Masaoka stage and completeness of resection was 0.78 (95% CI, 0.47–1.31; P = 
0.350; Table 3).  
DISCUSSION 
Although adjuvant RT has traditionally been performed for thymoma, many 
reports have reconsidered its supposed benefit in recent years11-13. However, 
retrospective cohort studies of the efficacy of PORT for thymic epithelial tumors have 
not resulted in a consensus5, 11, 14-16.  
The efficacy of PORT for stage II and stage III have historically been 
discussed separately because the former is considered an early-stage tumor with a low 
risk of recurrence, whereas the latter is an advanced-stage tumor with a relatively high 
risk of recurrence. Generally, for completely resected stage II thymoma, PORT is 
considered to have only minor efficacy11, 12, 14, 17. The conclusions for stage III thymic 
epithelial tumors are less agreed upon. One meta-analysis and a large-scale cohort 
study from Japan concluded that there was no statistically significant reduction in 
recurrence after RT11, 18. On the other hand, a systematic review and another large-scale 
cohort study from Europe both supported adjuvant therapy16, 17. The heterogeneity of 
the populations and the adjustments for covariates (or lack thereof) may have been 
responsible for the disparate results among these studies. 
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Analyzing thymic carcinomas and thymomas as a whole may present 
misleading results, because thymic carcinomas, not being associated with autoimmune 
diseases19, 20, behave more aggressively than thymomas that actually have a lower 
5-year survival proportion18, 19. This inevitably leads to a necessity for separate 
analyses of adjuvant therapy for thymic carcinomas and for thymomas. However, few 
systematic studies have been reported regarding thymic carcinoma alone21-26. Although 
little benefit of PORT for thymic carcinoma had been reported21, 23, a cohort study 
using the European Society of Thoracic Surgeons (ESTS) database recently reported a 
contribution of PORT to survival for thymic carcinoma without identifying the group 
who gain the benefit26. 
In Japan, the indication of PORT for thymic epithelial tumor is left up to the 
judgment of individual institutions because an integrated consensus concerning this 
issue does not exist. Within our database, about a quarter of stage II thymoma patients 
(23.8%) and half of stage III thymoma patients (45.6%) were irradiated postoperatively 
throughout the study period (1991 - 2010). The frequency of PORT, however, tended to 
decrease over time. The proportion of irradiated patients for stage II thymoma in the 
second half of the period (2001 to 2010) was notably lower than in the first half (1991 
to 2000; 17.2% vs. 44.0%). Similarly, the proportion of irradiated patients for stage III 
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thymoma in the second half of the period was lower than in the first half (41.0% vs. 
56.1%). These decreasing trends of PORT incidence may be attributable to practice 
changes in the wake of a nationwide Japanese cohort study by Kondo et al. in 2003, 
which questioned the validity of PORT18. 
However, in the Japanese article18 mentioned above, the data were analyzed 
without adjusting for covariates. As the results of a comprehensive review showed14, 27, 
PORT seemed to adversely impact recurrence for advanced thymoma. Our analysis 
before adjusting for covariates (Supplement 2) also showed a similar result. This is 
because the results of meta-analyses are influenced by any bias in the population if the 
data are not adjusted for covariates. In contrast, the analysis using the ESTS database16 
adjusted for propensity score showed favorable efficacy of adjuvant therapy for thymic 
epithelial tumors. However, because these statistically reliable results were for all 
staged thymic epithelial tumors, it is difficult to identify the group whom adjuvant 
therapy would benefit the most. 
We analyzed the efficacy of PORT using the JART database, which is a 
Japanese nationwide database, with emphasis on histology and Masaoka staging. The 
advantages of our analysis are the large scale of the cohort study, and the use of Cox 
regression analysis with adjustment for covariates. The RFS and OS of all eligible 
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patients in this study, when adjusted for staging, histology and surgical completeness, 
showed high HRs for stage III, thymic carcinoma, and incomplete resection 
(Supplement 2). With these results and the reasons mentioned before, thymic 
carcinomas and thymomas should be analyzed separately and that analyses should be 
stratified by the strong confounding factor, Masaoka staging (stage II vs. stage III). 
Although the RFS curve for stage II thymic carcinoma with or without PORT 
showed no significant difference by the log-rank test, upon visual inspection the two 
curves appeared to differ (Fig. 2a). We speculate that this statistical result was caused 
by a shortage of cases. The HR of RFS for combined stage II and III thymic 
carcinomas adjusted for staging and surgical completeness was very low. From this 
result, we conclude that PORT improved RFS for stage II and III thymic carcinomas. 
The treatment after relapse of thymic carcinoma varies widely among institutes 
because there is no consensus on the efficacy of chemotherapy for thymic carcinoma8, 9. 
This high variability among follow-up treatment methodologies may cause difficulty to 
use OS as a measure of prognosis, and RFS is more appropriate measure to evaluate 
PORT for thymic carcinomas. An additional analysis of the RFS HR of PORT for stage 
II and III thymic carcinomas adjusted for the variables listed in Table 2 and 
postoperative chemotherapy revealed that the HR and P-values were nearly identical to 
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those in Table 2 (Supplement 3). Most patients with thymic carcinoma (84.4% 
[124/147]) were completely resected in our study. Thus, the HR of RFS for those 
patients was 0.36 (95% CI, 0.20-0.65; P < 0.001; Supplement 4), which was almost 
identical to the result including the patients with residual tumors (<20% of tumor 
volume) (HR, 0.48; 95% CI, 0.30-0.78; P = 0.003; Table 2)． Despite the 
non-standardized follow-up schedule in the JART database, we believe that the effect 
of PORT on RFS cannot be overestimated. The reason is that PORT patients need to 
visit the hospital for more frequent and routine examinations than patients that do not 
receive PORT. On the basis of these results, we conclude that PORT had a positive 
impact on stage II and III thymic carcinomas. 
Our results for the RFS and OS of stage II thymoma were similar to those of 
the past study.11, 12 In contrast, regarding the adjuvant therapeutic effect for stage III 
thymoma—i.e., the controversial category—we applied additional subgroups (affected 
organ, WHO histological type, tumor size, residual tumor, and associated MG) to the 
analysis because of the lack of any significant improvement in RFS or OS in response 
to PORT. None of the subgroup analyses showed a favorable effect on RFS by PORT. 
We conclude, therefore, that PORT for stage III thymoma does not contribute to 





Since this is a database study, some limitations are inherent in the 
retrospective data collection. Follow-up schedules were not standardized, possibly 
resulting in bias towards null hypotheses. Further, the JART database lacks specific 
details of radiotherapy treatments and does not include information on any treatments 
performed after relapse; hence, we could not fully evaluate treatment efficacy after 
relapse. 
In addition, we could not evaluate the influence of postoperative 
chemotherapy because there were only a few patients who underwent it. A future 
prospective study whose population receives a consistent type of postoperative therapy 
for thymic carcinoma is essential. 
 
CONCLUSION 
In this database study using the JART database, PORT did not increase 
relapse-free survival or overall survival for stage II and III thymoma, but did increase 





 1. Levine GD, Rosai J. Thymic hyperplasia and neoplasia: a review of current 
concepts. Hum Pathol 1978;9(5):495-515. Available from 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation
&list_uids=361541. 
 2. Weissferdt A, Moran CA. Thymic carcinoma, part 1: a clinicopathologic and 




 3. Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas 
with special reference to their clinical stages. Cancer 1981;48(11):2485-92. Available from 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation
&list_uids=7296496. 
 4. Koga K, Matsuno Y, Noguchi M, Mukai K, Asamura H, Goya T, et al. A review of 
79 thymomas: modification of staging system and reappraisal of conventional division into 
invasive and non-invasive thymoma. Pathol Int 1994;44(5):359-67. Available from 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation
&list_uids=8044305. 
 5. Detterbeck FC, Asamura H, Crowley J, Falkson C, Giaccone G, Giroux D, et al. 
The IASLC/ITMIG thymic malignancies staging project: development of a stage 
classification for thymic malignancies. J Thorac Oncol 2013;8(12):1467-73. Available from 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation
&list_uids=24389429. 
 6. Shields TW. General Thoracic Surgery 1989;3rd edition:Chapter 91. 
 7. Onuki T, Ishikawa S, Yamamoto T, Ito H, Sakai M, Onizuka M, et al. Pathologic 
radioresponse of preoperatively irradiated invasive thymomas. J Thorac Oncol 
2008;3(3):270-6. Available from 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation
&list_uids=18317070. 
 8. Attaran S, McCormack D, Pilling J, Harrison-Phipps K. Which stages of 
thymoma benefit from adjuvant chemotherapy post-thymectomy? Interact Cardiovasc 





 9. Okuma Y, Hosomi Y, Takagi Y, Sasaki E, Hishima T, Maeda Y, et al. Clinical 
outcomes with chemotherapy for advanced thymic carcinoma. Lung Cancer 
2013;80(1):75-80. Available from 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation
&list_uids=23313005. 
 10. Gomez D, Komaki R, Yu J, Ikushima H, Bezjak A. Radiation therapy 
definitions and reporting guidelines for thymic malignancies. J Thorac Oncol 2011 
6(7 Suppl 3):S1743-8. Available from 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation
&list_uids=21847057. 
 11. Korst RJ, Kansler AL, Christos PJ, Mandal S. Adjuvant radiotherapy for 
thymic epithelial tumors: a systematic review and meta-analysis. Ann Thorac Surg 
2009;87(5):1641-7. Available from 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation
&list_uids=19379938. 
 12. Mangi AA, Wright CD, Allan JS, Wain JC, Donahue DM, Grillo HC, et al. 




 13. Mangi AA, Wain JC, Donahue DM, Grillo HC, Mathisen DJ, Wright CD. 
Adjuvant radiation of stage III thymoma: is it necessary? Ann Thorac Surg 
2005;79(6):1834-9. Available from 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation
&list_uids=15919266. 
 14. Detterbeck FC. Evaluation and treatment of stage I and II thymoma. J Thorac 
Oncol 2010;5(10 Suppl 4):S318-22. Available from 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation
&list_uids=20859126. 
 15. Haniuda M, Miyazawa M, Yoshida K, Oguchi M, Sakai F, Izuno I, et al. Is 




 16. Ruffini E, Detterbeck F, Van Raemdonck D, Rocco G, Thomas P, Weder W, et al. 
Tumours of the thymus: a cohort study of prognostic factors from the European Society of 
20 
 
Thoracic Surgeons database. Eur J Cardiothorac Surg 2014. Available from 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation
&list_uids=24482389. 
 17. Falkson CB, Bezjak A, Darling G, Gregg R, Malthaner R, Maziak DE, et al. 
The management of thymoma: a systematic review and practice guideline. J Thorac Oncol 
2009;4(7):911-9. Available from 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation
&list_uids=19557895. 
 18. Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of 




 19. Detterbeck FC, Parsons AM. Thymic tumors. Ann Thorac Surg 
2004;77(5):1860-9. Available from 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation
&list_uids=15111216. 
 20. Suster S, Rosai J. Thymic carcinoma. A clinicopathologic study of 60 cases. 
Cancer 1991;67(4):1025-32. Available from 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation
&list_uids=1991250. 
 21. Weksler B, Dhupar R, Parikh V, Nason KS, Pennathur A, Ferson PF. Thymic 
carcinoma: a multivariate analysis of factors predictive of survival in 290 patients. Ann 
Thorac Surg 2013;95(1):299-303. Available from 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation
&list_uids=23141529. 
 22. Okereke IC, Kesler KA, Freeman RK, Rieger KM, Birdas TJ, Ascioti AJ, et al. 
Thymic carcinoma: outcomes after surgical resection. Ann Thorac Surg 2012;93(5):1668-72; 
discussion 72-3. Available from 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation
&list_uids=22421590. 
 23. Song Z, Zhang Y. Adjuvant therapy in stage II thymic carcinoma. J Cancer Res 
Clin Oncol 2014;140(2):349-52. Available from 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation
&list_uids=24305755. 
 24. Zhao Y, Zhao H, Hu D, Fan L, Shi J, Fang W. Surgical treatment and prognosis 
21 
 
of thymic squamous cell carcinoma: a retrospective analysis of 105 cases. Ann Thorac Surg 
2013;96(3):1019-24. Available from 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation
&list_uids=23866799. 
 25. Yano M, Sasaki H, Yokoyama T, Yukiue H, Kawano O, Suzuki S, et al. Thymic 
carcinoma: 30 cases at a single institution. J Thorac Oncol 2008;3(3):265-9. Available from 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation
&list_uids=18317069. 
 26. Ruffini E, Detterbeck F, Van Raemdonck D, Rocco G, Thomas P, Weder W, et al. 
Thymic carcinoma: a cohort study of patients from the European society of thoracic 
surgeons database. J Thorac Oncol 2014;9(4):541-8. Available from 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation
&list_uids=24736078. 
 27. Ruffini E, Mancuso M, Oliaro A, Casadio C, Cavallo A, Cianci R, et al. 
Recurrence of thymoma: analysis of clinicopathologic features, treatment, and outcome. J 

















Male 49 (61.3) 49 (65.3) 
 
Female 31 (38.8) 26 (35.7) 
 
Age (y)  
  
0.842 
mean ± SD 60.3±11.5 59.9±12.3 
 
median (range) 61.5 (36-79) 60 (23-86) 
 
Tumor size on imaging (cm) 
  
0.440 
mean ± SD 5.3±2.3 * 5.6±2.3 ** 
 
median (range) 5.3 (0-10) * 5.6 (1.8-11) ** 
 
Masaoka stage             
  
0.314 
Stage II 25 (31.3) 30 (40.0) 
 
Stage III 55 (68.8) 45 (60.0) 
 
Completeness of Surgery  
  
0.048 
macroscopic total 69 (86.3) 72 (96.0) 
 
subtotal 11 (13.8) 3 (4.0) 
 
Residual tumor    0.290 
microscopic 8 (10.0) 10 (13.3)  
macroscopic  8 (10.0) 0 (0.0)  
no 64 (80.0) 65 (86.7)   
Myasthenia gravis              
  
1 
yes 1 (1.3) 1 (1.3) 
 





yes 17 (21.3) 5 (6.7) 
 
no 62 (77.5) 70 (93.3) 
 
missing 1 (1.3) 0 (0.0) 
 
PORT = postoperative radiotherapy, SD = standard deviation 
 
subtotal; surgically resected >80% tumor volume 
 
Data are shown as mean ± standard deviation  
* Data available for 77 patients 
 





TABLE 1b.  Patient Characteristics of Thymoma    
 No. (%)  
Variables with PORT  (n=323) 
without PORT 
 (n=787) p-value 
Gender    0.649 Male       144 (44.6) 332 (42.2)  Female 179 (55.4) 454 (57.7)  missing 0 1  Age (y)    <0.001 
mean±SD 54.0±12.7 58.4±13.5  
median (range) 55 (21-82) 60 (18-86)  Tumor size on imaging (cm)   0.017 
mean ± SD 5.6±2.5 * 5.2±2.5 **  
median (range) 5 (0-18) * 5 (1-30) **  WHO histological type    <0.001 Type A 15 (4.6) 57 (7.2)  Type AB 67 (20.7) 231 (29.4)  Type B1 68 (21.1) 181 (23.0)  Type B2 106 (32.8) 207 (26.3)  Type B3 67 (20.7) 111 (14.1)  Masaoka stage              <0.001 Stage II 200 (61.9) 640 (81.3)  Stage III 123 (38.1) 147 (18.7)  Completeness of Surgery    <0.001 macroscopic complete 306 (94.7) 782 (99.4)  subtotal resection 17 (5.3) 5 (0.6)  Residual tumor                   <0.001 
microscopic (+) 35 (10.8) 17 (2.2)  
macroscopic(+) 7 (2.2) 2 (0.3)  
no 281 (87.0) 768 (97.6)   
Myasthenia Gravis                0.482 yes 80 (24.8) 179 (22.7)  no 242 (74.9) 605 (76.9)  missing 1 (0.3) 3 (0.5)  Postoperative chemotherapy     0.282 yes 10 (3.1) 16 (2.0)  no 311 (96.3) 767 (97.5)  missing 2 (0.6) 4 (0.5)  
SD = standard deviation 
PORT = postoperative radiotherapy, WHO = World Health Organization 
Data are shown as mean ± standard deviation 
subtotal; surgically resected >80% tumor volume 








TABLE 2. Analyses of relapse-free survival in thymic carcinoma and thymoma 
  Thymic carcinoma Thymoma 
 
HR (95% CI) p-value HR (95% CI) p-value 
PORT                  
(yes/ no) 
0.48 (0.30 0.78) 0.003 0.98 (0.70 1.37) 0.905 
Masaoka stage         
(stage III/ stage II) 
3.51 (1.86 6.65) < 0.001 4.54 (3.27 6.32) < 0.001 
Residual tumor                 
(yes/ no) 
1.93 (1.09 3.42) 0.023 2.01 (1.22 3.29) 0.006 
RFS; relapse free survival 
   
 
HR; hazard ratio 
   
CI; confidential interval 
   
PORT; postoperative radiotherapy 
   




TABLE 3. Analyses of overall survival in thymic carcinoma and thymoma 
  Thymic carcinoma Thymoma 
 
HR (95% CI) p-value HR (95% CI) p-value 
PORT                 
(yes/ no) 
0.94 (0.51 1.75) 0.850 0.78 (0.47 1.31) 0.350 
Masaoka stage     
(stage III/ stage II) 
3.08 (1.37 6.94)  0.007 3.31 (2.03 5.41) <0.001 
Residual tumor             
(yes/ no) 
1.32 (0.65 2.70) 0.446 1.48 (0.64 3.40) 0.355 
OS; overall survival 
    
HR; hazard ratio 
   
 
CI; confidential interval 
   
PORT; postoperative radiotherapy 
   
 









Figure 1. Scheme of study population. 
 
Figure 2. Kaplan–Meier plots and the log-rank P-value comparing PORT to no 
PORT. (a) Relapse-free survival for stage II thymic carcinoma. (b) Relapse-free 
survival for stage III thymic carcinoma. (c) Relapse-free survival for stage II 
thymoma. (d) Relapse-free survival for stage III thymoma. 
 
Figure 3. Forest plot of subgroup analyses comparing PORT to no PORT for 
patients with stage III thymoma. The squares represent the hazard ratio of each factor. 
Each hazard ratio represents the ratio comparing PORT to no PORT. The horizontal 
bars running through each square represent the 95% confidence interval. Factors with 
<50 cases were excluded. HR: hazard ratio, CI: confidence interval. 
 
Figure 4.  Kaplan-Meier plots and the log-rank P-value comparing PORT to no 
PORT. (a) Overall survival for stage II thymic carcinoma. (b) Overall survival for stage 
III thymic carcinoma. (c) Overall survival for stage III thymoma. (d) Overall survival 
for stage III thymoma. 
Inclusion criteria(1) eliminated by histology  (n = 106) 
breakdown: neuroendocrine tumor (64), missing(42) 
Inclusion criteria(2) eliminated by Masaoka staging (n = 1,310) 
breakdown:  stage I (957), stage IVa(181), stage IVb(123), missing(49) 
Patients included in the JART database (n=2835) 
Patients meeting the inclusion criteria (1) (n=2729) 
Patients meeting the criteria (1) and (2) (n=1419) 
With postoperative radiotherapy (n = 403) Without postoperative radiotherapy (n = 862) 
Exclusion criteria (1) (n = 38) completeness of resection 
breakdown: resected under 80% of tumor volume(21), missing(17) 
Patients meeting the eligibility criteria (n=1381) 
Patients available for analysis (n = 1,265) 
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n = 1220  p = 0.056
Supplement 1. Relapse-free survival for stage II/III thymic 
carcinoma and thymoma comparing PORT to no PORT.
Supplement 2; Cox regression analysis for RFS adjusted for pathology, Masaoka 
staging and residual tumor
Parameter HR (95% CI) p-value
PORT   (yes/ no) 0.76 (0.58 1.01) 0.116
Pathology   (Thymic carcinoma/ Thymoma) 2.51 (1.87 3.38) < 0.001
Masaoka stage   (stage III/ stage II) 4.46 (3.33 5.99) < 0.001





Supplement 3; Cox regression analysis for RFS of thymic carcinoma adjusted for 
pathology, Masaoka staging, residual tumor and postoperative chemotherapy
Parameter HR (95% CI) p-value
PORT   (yes/ no) 0.48(0.29 0.78) 0.003
Masaoka stage  (stage III/ stage II) 3.32(1.74 6.36) < 0.001
Residual tumor   (yes/ no) 1.99 (1.11 3.55) 0.020





Supplement 4; Cox regression analysis for RFS of completely resected 
thymic carcinoma adjusted for pathology, Masaoka staging 
HR (95% CI) p-value
PORT   (yes/ no) 0.36 (0.20 0.65) < 0.001
Masaoka stage   (stage III/ stage II) 3.72 (1.93 7.17) < 0.001
HR; hazard ratio
CI; confidential interval
PORT; postoperative radiotherapy
Supplement 4
